Showing results (1291-1300 of 1,431) with videos related to

Sort By:
Pageof 144
The Lancet. Oncology|February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trialAmit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancerSharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
JAMA Oncology|October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With RucaparibTanya T Kwan, Amit M Oza, Anna V Tinker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 21, 2020
Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancersSoyoun Rachel Kim, Alicia Tone, Raymond Kim, et al.
British Journal of Cancer|April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerYvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 22, 2019
ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairsMarina T DiStefano, Sarah E Hemphill, Andrea M Oza, et al.
The Lancet. Oncology|April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trialMichael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 22, 2024
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literatureChristopher Iriarte, Jennifer E Yeh, Allireza Alloo, et al.
Journal of Cardiovascular Electrophysiology|December 2, 2025
Patient and Procedural Factors Associated With Same-Day Discharge Following Pulsed Field Ablation for Atrial Fibrillation: Insights From the DISRUPT-AF RegistryAmin Al-Ahmad, Jose Osorio, John Day, et al.
The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Pageof 144